Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1152.50    34.50 (3.09%)
Bid:
1156.50
Ask:
1157.00
Spread: 0.50 (0.043%)
Market Cap: £9.75b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Acquisition

5 Jan 2016 07:00

RNS Number : 7712K
Smith & Nephew Plc
05 January 2016
 

 

 

 

Smith & Nephew completes acquisition of surgical robotics business Blue Belt Technologies

 

5 January 2016

 

 

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces it has completed the acquisition of Blue Belt Holdings, Inc. ("Blue Belt Technologies"), securing a leading position in the fast-growing area of orthopaedic robotics-assisted surgery.

 

Blue Belt Technologies' Navio surgical system currently provides robotics-assistance in unicondylar or partial knee replacement surgery through CT-free navigation software and a unique hand-held, robotic bone-shaping device. Navio and Smith & Nephew's partial knee implant portfolio form a strong combined business from which to accelerate growth in this attractive area of surgery. Additionally, the Group intends to expand the Navio platform into total knee, bi-cruciate retaining knee and revision knee implants, delivering significant further upside.

 

Enquiries

 

InvestorsIngeborg ØieSmith & Nephew

 +44 (0) 20 7960 2285

 

Financial MediaCharles ReynoldsSmith & Nephew

+44 (0) 20 7401 7646

 

Ben Atwell / Matthew ColeFTI Strategic Consulting

 

+44 (0) 20 3727 1000

 

Trade Media

Joe Metzger

Smith & Nephew

 

 

+1 (978) 749-1330

 

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 14,000 employees and a presence in more than 100 countries. Annual sales in 2014 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

 

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

 

◊Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQEAKFLEEDKEFF
Date   Source Headline
25th May 20216:15 pmRNSDirector/PDMR Shareholding
21st May 20214:30 pmRNSDirector/PDMR Shareholding
18th May 20215:15 pmRNSDirector/PDMR Shareholding
14th May 20214:00 pmRNSDirector/PDMR Shareholding
11th May 20212:32 pmRNSHolding(s) in Company
4th May 202112:38 pmRNSTotal Voting Rights
4th May 20219:45 amRNSDirector/PDMR Shareholding
29th Apr 20217:00 amRNSTrading Statement
28th Apr 20217:00 amRNSDividend Declaration
14th Apr 20216:04 pmRNSResult of AGM
1st Apr 20211:15 pmRNSTotal Voting Rights
1st Apr 20219:00 amRNSDirector Declaration
31st Mar 202110:00 amRNSAdditional Annual General Meeting update
19th Mar 20211:00 pmRNSDirector/PDMR Shareholding
19th Mar 20219:00 amRNSNotice of Results
17th Mar 20213:30 pmRNSDirector/PDMR Shareholding
10th Mar 20215:45 pmRNSDirector/PDMR Shareholding
9th Mar 20215:48 pmRNSDirector/PDMR Shareholding
8th Mar 202111:30 amRNSDirector/PDMR Shareholding
1st Mar 20214:18 pmRNSAnnual Financial Report
1st Mar 20211:00 pmRNSTotal Voting Rights
18th Feb 20217:00 amRNSFourth Quarter and Full Year 2020 Results
11th Feb 20217:00 amRNSDirector Declaration
10th Feb 20217:00 amRNSJohn Ma joins Smith+Nephew's Board as NED
3rd Feb 20215:00 pmRNSDirector/PDMR Shareholding
1st Feb 20211:41 pmRNSBlock listing Interim Review
1st Feb 202112:30 pmRNSTotal Voting Rights
29th Jan 20217:00 amRNSNotice of Results
28th Jan 20219:15 amRNSDirector Declaration
14th Jan 202111:30 amRNSDirector/PDMR Shareholding
11th Jan 20217:00 amRNSTrading Statement
6th Jan 20211:00 pmRNSDirectorate Change
4th Jan 20215:46 pmRNSSmith+Nephew Completes Orthopaedics Acquisition
4th Jan 202111:00 amRNSTotal Voting Rights
22nd Dec 20209:00 amRNSDirector/PDMR Shareholding
1st Dec 202012:40 pmRNSTotal Voting Rights
24th Nov 20203:30 pmRNSDirector/PDMR Shareholding
16th Nov 20203:30 pmRNSDirector/PDMR Shareholding
10th Nov 20207:00 amRNSDirector/PDMR Shareholding
10th Nov 20207:00 amRNSTotal Voting Rights
3rd Nov 202010:00 amRNSDirector/PDMR Shareholding
2nd Nov 20205:04 pmRNSDirector/PDMR Shareholding
2nd Nov 20202:45 pmRNSTotal Voting Rights
29th Oct 20203:05 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSTrading Statement
20th Oct 202010:00 amRNSKatarzyna Mazur-Hofsaess joins Smith+Nephew as NED
15th Oct 202011:52 amRNSDividend Declaration
9th Oct 20209:08 amRNSNotice of Results
8th Oct 20207:00 amRNSSmith+Nephew Prices USD Bond Issue
1st Oct 202011:08 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.